Needle injecting into the top of vaccine bottle

UK Government secures two million additional vaccine doses

As the UK Government continues to work to strike deals with manufacturers to secure additional doses of promising Covid-19 vaccine candidates, it has announced a further two million doses have been agreed.

The latest deal, which relates to doses of the Moderna vaccine candidate, brings the total number of secured doses for this particular vaccine to seven million – enough to potentially inoculate around 3.5 million people around the UK.

Before it can be approved for UK use, the vaccine must still meet the strict standards of safety and effectiveness of the independent medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).

If approval is achieved, the seven million secured doses could start to be delivered to the UK as early as Spring 2021 – the same timetable as with other European nations.

As part of its national Covid-19 vaccination strategy, the UK Government has worked to strike deals with a diverse portfolio of manufacturers of promising vaccine candidates. Across deals with seven different vaccine developers, the UK now currently has secured around 357 million vaccine doses.

Business Secretary Alok Sharma said: “It is essential that we continue to bolster our portfolio of vaccine candidates to ensure we’re in the best possible position to protect the public once we see that breakthrough.

“The UK was one of the first countries in Europe to sign a deal with Moderna, and I’m delighted we have been able to secure a further two million doses of their promising candidate for the British public.”

The vaccine candidate has, at present, shown itself to be one of the most promising candidates, with preliminary clinical trial results showing it to be nearly 95% effective in protecting against Covid-19, with no safety issues reportedly identified to date.

The safety data is still yet to be released by the manufacturer to show whether the vaccine is both safe and effective.

It is currently still conducting phase three clinical trials of the vaccine, which utilises mRNA vaccine technology.

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all